NATICK, Mass., Jan. 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced the international launch and first implantation of the PROMUS(TM) Everolimus-Eluting Stent, making Boston Scientific the only company to offer two distinct drug-eluting stent (DES) platforms. PROMUS is a private-labeled XIENCE(TM) V Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. The PROMUS Stent received CE Mark approval in October 2006 which allows Boston Scientific to distribute the stent in select countries of the European Economic Area. It will also be available in selected countries in Asia, Latin America and Eastern Europe. A U.S. launch is planned for 2008.
Dr. Willibald Maier performed the procedure on December 21, 2006 at University Hospital in Zurich, Switzerland, marking the first implantation of the PROMUS Stent.
“I am excited to have been a part of the first use of Boston Scientific’s new drug-eluting stent,” said Dr. Maier. “The PROMUS Stent provides patients a treatment option that offers an Olimus drug on a highly deliverable platform, and we are pleased to have it available for our patients.”
“The addition of the PROMUS Stent gives Boston Scientific the ability to offer clinicians two highly deliverable options -- our market-leading TAXUS(R) Paclitaxel-Eluting Stent and PROMUS, our high-potential Everolimus-Eluting Stent,” said Paul LaViolette, Chief Operating Officer of Boston Scientific. “The PROMUS Stent complements our broad DES portfolio and further reinforces Boston Scientific’s leadership in the DES market, as well as our commitment to continued innovation.”
Positive results for the XIENCE V Stent were reported from the SPIRIT II clinical trial at the World Congress of Cardiology in Barcelona, Spain, demonstrating that the XIENCE V Stent met its primary endpoint of non- inferiority to the TAXUS Stent as measured by late loss at six months. Boston Scientific’s TAXUS Stent System has a record of proven outcomes, including three million TAXUS Stents implanted in patients worldwide and clinical follow-up on more than 4,000 patients out to four years.
PROMUS and TAXUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott. The SPIRIT Clinical Program is sponsored by Abbott. The PROMUS Stent is not approved for sale in the U.S.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devises whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific’s over all business strategy, and other factors described in Boston Scientific’s filings with the Securities and Exchange Commission.
CONTACT: Paul Donovan 508-650-8541 (Office) 508-667-5165 (Mobile) Media Relations Boston Scientific Corporation Dan Brennan 508-650-8538 (Office) 617-459-2703 (Mobile) Investor Relations Boston Scientific Corporation Boston Scientific Corporation
CONTACT: Media Relations, Paul Donovan, +1-508-650-8541, or mobile,+1-508-667-5165, or Investor Relations, Dan Brennan, +1-508-650-8538, ormobile, +1-617-459-2703, both of Boston Scientific Corporation
Web site: http://www.bostonscientific.com//
